New treatment for cancer, hope for patients with little chance of survival

Immunosis uses the immune system to kill cancer cells and can save lives when other treatment options, such as surgery, radio therapy, or chemotherapy, are not producing results.

Now oncologists in the United Kingdom have found a treatment of immun therapy combined with guadecitaby, a new experimental drug that can change cancer resistance to immun therapy. Patients who were expected to die after all treatment options had failed lived for a long time, they say.

The combination of pembrollizumab, an immun therapy drug, and guadecibine, prevented the progress of cancer in more than a third of patients registered in early testing of the first phase, reports abcnews.al.

The results were published in the Journal for Immmune Therapy of Cancer. Double combination could become an effective new weapon against certain forms of cancer, said experts at the Cancer Research Institute and the Royal Marsden Foundation.

Patients, from the Royal Marsden Hospital and University College London, included those with lung cancer, breast, prostate and intestines.

“Immmunosis has shown amazing results in cancer care over the past decade, but it doesn't work well in all cancers and cancers can often become resistant. This combination may be a way to combat cancer even after he stopped reacting to immunosis,” said research director Annna Minchom, a scientist and oncologist.